Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection
BACKGROUND: Venous thromboembolism or extensive thrombosis is relatively common in patients with severe COVID-19 infection and has been associated with increased mortality. During the current COVID-19 pandemic, several prophylactic doses and types of low-molecular-weight heparin (LMWH) are being use...
Main Authors: | Kadir Canoglu, Bengu Saylan |
---|---|
Format: | Article |
Language: | English |
Published: |
King Faisal Specialist Hospital and Research Centre
2020-12-01
|
Series: | Annals of Saudi Medicine |
Online Access: | https://www.annsaudimed.net/doi/full/10.5144/0256-4947.2020.462 |
Similar Items
-
Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential
by: Olexandr Kamyshnyi, et al.
Published: (2021-12-01) -
Comparison of non-severe COVID-19 pneumonia patients treated with lopinavir/ritonavir and favipiravir
by: Bengü Şaylan, et al.
Published: (2020-11-01) -
Venous thrombotic events in severe and critically COVID-19 patients despite high dose prophylactic low-molecular-weight heparin
by: Chantal Visser, et al.
Published: (2020-12-01) -
COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
by: Alessandra F. Perna, et al.
Published: (2020-05-01) -
Retrospective analysis of severe COVID-19 pneumonia patients treated with lopinavir/ritonavir: A comparison with survivor and non-survivor patients
by: Omer Ayten, et al.
Published: (2020-12-01)